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4:oo p.m. 
860-1 The Design, Synthesis and Cardiorenal Actions of a 
New Chimeric Natriuretic Peptide CD-NP 
Ondrei Lisy, John C. Burnett, Jr., Mayo Clinic, Rochester, MN 
Background: C-type natriuretic peptide (CNP) is a 22.amino-acid (AA) peptide of endot- 
helial cell origin which is powerful venodilator but lacks renal adions. Dendroaspis natri- 
uretic peptide (DNP) is a recently discovered 38-AA peptide structurally similar to ANP, 
BNP and CNP with potent natriuretic and vasoactive actions. Data suggest that among 
natriurebc peptides DNP may be the most resistant to degradation by neutral endopepti- 
dase which may contribute to enhanced biological actions. 
Methods: Based upon such potent biological properties of both peptides, we designed, 
synthesized and assessed the cardiorenal actIons of a chimeric peptide CD-NP. which 
possesses the 22.AA core ring structure of CNP and the 15.AA linear C-terminus of 
DNP. We assessed the therapeutic potential of parenterally administered CD-NP upon 
cardiorenal and endocrine function in 6 normal anesthetized dogs. Intravenous CD-NP 
was infused after baseline measurements at 10, 50 and 100 ngikglmln. * ~~0.05 vs. 
baseline. 
Results: Administration of low, medium and high dose CD-NP decreased MAP (from 
baseline 137+6 to 13426 and 126+5 and 118*6* mmHg), RAP (from 1.0+0.3 to 0.5*0.4 
and -0.03iO.6’ and -0.4*0.6’ mmHg) and PCWP (from 6.4eO.4 to 5.2~0.5’ and 4.4iO.6’ 
and 3.6tO.5’ mmHg). These actions were associated with a decrease ln heart rate (from 
130+2 to 124+5 and 115*3’ and 11924 bpm). CD-NP increased GFR (from 37~3 lo 
3322 and 50+8 and 55+6’ mllmin), enhanced natriuresis (UNaV from 48+17 lo 123i23 
and 326+51’ and 462*69* pEqimin) and diuresis (UV from 0.7+0.2 to 1.7iO.3 and 
4.0+0.7* and 4.5+0.7’ ml/min) and activated cGMP in plasma (from 8.5~1.5 to 13.5-tl.6 
and 28.1*2.1* and 50.lr2.1’ pmollml) and urine. All three doses of CD-NP decreased 
plasma renin activity (from 8.2+1 to 5.9*1’ and 3.9kO.7’ and 6.3il .l’ nglmlihr). 
Conclusion: We repo;t the design, synthesis and cardiorenal actions of a new chimeric 
peptide CD-NP. which activates the cGMP pathway, reduces cardiac filling pressures. 
augments natriuresis and diuresis and possesses renin-suppressing properties. These 
findings support a possible therapeutic role for this new designer peptide in the treatment 
of cardiovascular diseases such as heart failure and hypertension. 
4:15 p.m. 
860-2 Angiotensin II Type 1 Receptor and Endothelin Type A 
Receptor Antagonists Prevent Ventricular Fibrosis in 
the Hypertensive Heart Through Different Mechanisms 
Junichl Yoshida, Kazuhlro Yamamoto, Toshiaki Mano, Yasushi Sakata, Nagahlro 
Nishikawa, Masatsugu Hod. Tohur Masuyama. Osaka University Graduate School of 
Medicine, Osaka, Japan 
Background: LV fibrosis contributes to the development of heart failure. Extracellular 
matrix (ECM) is regulated by its synthesis and degradation, and the balance between 
matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) 
mainly determlnes the degradation. Blockade of renin-angiotensin and endothalin sys- 
tems prevented the transition to overt heart failure in hypertensive hearts and their bene- 
ficial effects were accompanied wth inhibition of LV fibrosis. However, mechanisms how 
the antagonists exerl their effects on ECM regulatory system remain unclear. 
Methods: Dahl salt-sensitive rats (DSR) fed on 8% NaCl from 7wks were divided into 3 
groups: 6 untreated rats, 6 rats treated with subdepressor dose of anglotensin II type 1 
receptor antagonist (ARB), candesartan. since 8 wks, and 6 rats treated with subdepres- 
sor dose of endothelin type A receptor antagonist (ETB), TA-0201, since 8 wks. Six DSR 
fed on normal chow sewed as control. 
Result: Data at 13 wks are shown in the table. ARB and ETB similarly Inhibited fibrosis. 
ARB, not ETB, normalized collagen mRNA level. ETB suppressed gene expression of 
TIMP-2 without affecting that of MMP-2 and increased a ratio of MMP-2 lo TIMP-2 mRNA 
levels. ETB provided greater gelatinolytic activity as assessed with in vitro gelatin zymog- 
raphy than ARB, suggesting augmented collagen degradation in the rats treated with 
ETB. 
Conclusion: ARB and ETB inhibit ventricular fibrosis through different modulation of 
ECM regulatory system. 
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end diastolic pressure. 
4:30 p.m. 
860-3 Comparison of Vasodilation by CVT-3146, a Novel A2, 
Receptor Agonist, and Adenosine in Different Vascular 
Beds in Awake Dogs 
Gona Zhao, Axel Linke, Xiaobin Xu, Manuel Ochoa, Francis Belloni, Luiz Belardinelli, 
Thoams Hintze, CV Therapeutics, Palo Alto, CA, New York Medical College, Valhalla, 
NY 
Background: We have previously shown in awake dogs that CVT-3146 (CVT) causes a 
smaller decrease in total peripheral resistance compared to adenosine (ADO), but it 
causes an equal or greater increase in coronary blood flow than ADO. In this study. we 
compared vasodilator effects of CVT to those of ADO in different vascular beds in awake 
dogs. 
Methods: Dogs were chronically instrumented for measurements of the blood flow in 
coronary (CBF), mesenteric (MBF), hindlimb (LBF), and renal (RBF) vascular beds, and 
hemodynamics. 
Resulta: Bolus injections (iv) of CVl (0.1 to 2.5pglkg) and ADO (10 to 250W/kg) caused 
significant increases in CBF (35+6 to 205*23% and 58+13 to 163*18%) and MBF (18~4 
to 88+14% and 36*8 to 84+5%). CVT is a more potent and longer lasting coronary 
vasodilator compared to ADO (the duration for CBF above P-fold of the baseline: CVT 
(2.5&kg): 130tl9s; ADO (250@kg): 16+3s, PcO.05). As shown in the figure 
(mean*SE. n=6), CVT caused a smaller increase in LBF than ADO. ADO caused a dose- 
dependent renal vasoconstriction (RBF -46*7 lo -85+4%), whereas CVT has no or a llttle 
effect on RBF (-522 to -11+4%, PcO.05, compared to ADO). 
Conclusion: CVT-3146 is a more selective and potent coronary vasodilator than ADO. 
CVT-3146 has no significant effect on renal blood flow in awake dogs. These features of 
CVT-3146 make it an ideal candidate for radionuclide myocardial perfusion imaging. 
4:45 pm. 
660-4 A New Perspective on the Pharmacological Treatment 
of Vagal Induced Atrial Fibrillation: Combined Inhibition 
of Muscarnic Potassium Current and IKr 
Bodo Brandt?, Marc Van Bracht, Rolf Borchard, lngo Wickenbrock, Daniel Dlrkmann, 
Magnus Prull, Nadme Bodanowski. Hans-Joachim Trappe, University of Bochum, Herne, 
Germany 
Background: Pharmacological treatment of atrial fibrillation (AF) is limited by Induction of 
malignant ventricular arrhythmias. Developing new drugs one promising strategy is a 
more specific treatment of the atria. Muscarinic potassium current (IK(ACh)) is predomi- 
nantly expressed in supraventricular tlssua. We studied the profile of representative class 
III drugs in respect to their effect on IK(ACh). 
Methods: In guinea-pig atrial myocytes IK(ACh) was activated by using acetylcholine 
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(ACh) or adenosme (Ado) Drugs used: Selective IKs blocker chromanole 2938 (Cm); IKr 
blocker sotalol (Sot), dofetilide @of), lbutilide (Ibu), and RP58866 (F(P). Data are 
expressed as mean values *standard deviation. 
Results: ACh induced IK(ACh) density was 94il2 pAipF. IK(ACh) was almost com- 
pletely desensitlsed in the presence of 50 pM Ter. Ibu, or Dof. IC50 of IK(ACh) inhlbition 
by the three drugs was 4.8, 2.8, and 0.9pM (Ter, Ibu, Dof respectively; n=9). Ado induced 
and receptor independent GTP-g-S induced IK(ACh) was sensitive to Ter, Ibu, and Dof 
as well. Drug potency was not affected by the way of current activation (Ado, ACh, GTP- 
g-S; (n=7)). Sot is known to be a weak inhibitor of IKr. Inhibition of IK(ACh) by Sot was 
much less potent (IC50=35SvM; n=lZ) than inhibition by the high affinity IKr-blocker Ter. 
Ibu, and Dof. Sup&u&on of the cells with the IKs-blocker Cro showed no desensitisatlon 
of IK(ACh) (highest concentration used was 100pM). Applied via the patch pipette 
(4Omin) none of the class Ill drugs were effective. 
Conclusions: In contrast to the selective IKs blocker Cm the IKr blocker Sot, Dof, and Ibu 
induced a concentration dependent inhibition of IK(ACh). The weak IKr blocker Sot 
showed the highest IC50 value indicating inhibItIon of IK(ACh) and IKr but not IKs to be of 
slm!lar mechanism. Experiments with GTP-g-S and intracellular drug application suggest 
a direct channel blockade by the compounds. Additive desensitisation of muscarinic 
potassium current would be of clinical relevance especially in vagal induced AF. The pre- 
sented data could be the basis for a more specific antiarrhythmic therapy of vagal 
induced AF paralleled by a reduction of proarryhthmic side effect at the ventricular level. 
ORAL CONTRIBUTIONS 
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665-l Dilated Cardiomyopathy and Cardiac Arrhythmias in the 
Transgenic Mice Overexpressing Mouse Cardiac 
Junctate-1 
Myeong-Chan Cho. So-Young Choi, Young-Hwa Kim, Jin-Sook Kwon, Hainan Plao. Tae_ 
Jinx Dong-Woon Kim, Chang-Soo Hong, Do Han Kim, Chungbuk National 
University Hospital, Cheongju, South Korea, Kwangju Institute of Science and 
Technology, Kwangju, South Korea 
Junctate is a high capacity Ca2+ btnding protein in the SWER and is an alternative splic- 
ing form of the same gene generating junctin. We recently repotted the cardiac pheno- 
type of juntln transgenic (TG) mice (FASEB J 2002:16:1310) and cloned 3 complete 
cDNAs homologous to human junctate through screening of a cDNA library. Each junc- 
tate was composed of 270 (junctate-1). 259 and 215 amino acids. To elucidate the func- 
tional role of junctate in heart, junctate-1 TG mice were generated under the control of 
mouse aMHC promoter. TG rmce had severe cardiac hypertrophy (Z-fold increase in 
mass compared with their littermates) with biatrial and biventricular enlargement, focal 
areas of fibrosis, and intraatrial thrombl, accompanied by slow heart rate and fluid reten- 
tion. Microscopic exammation of TG hearts revealed generalized hypertrophy with fibro- 
sis. Ultrastructural analysis demonstrated that mitochondria showed scattered pattern 
through the sarcoplasm and sarcoplasmic reticulum was frustrated and many my&n-like 
structures were also appeared in the sarcoplasm of the TG myocytes. As assessed by 
echocardiography, LV end-systolnc and end-diastolic dimension was increased and LV 
systolic function was moderately depressed (fractional shortening; TG 347*9.2% vs Wl 
48.3+7.5%) (p<O.O05). In addition to bradycardia, various forms of cardiac arrhythmias 
such as ventricular premature beats, atrial fibrillation or sinus pause were obsewed in the 
young TG mice. In TG hearts, the expression levels of calreticulin and SERCAZa were 
significantly decreased without any changes !n other EC coupling protems such as 
DHPR. calsequestrin, tnadin, juncttn and phospholamban. Bmax of ryanodine binding 
decreased without change in Kd. Those morphological, phystological and electrical alter- 
ations could be caused by the perturbations of the intracellular Ca” homeostasis due to 
the overexpress~on of junctate-1 .This model may be helpful to investigate the molecular 
framework involved in the development of cardiac hypertrophy and failure and to eluci- 
date the relationship between altered expression of ]unctional SR proteins and the patho- 
genws of cardiac remodeling and arrhythmia generation. 
865-2 
4:15 p.m. 
Efficient Gene Delivery Into Undifferentiated Stem Cells 
and Differentiated Cardiomyocytes Using Lentiviral 
Vectors 
Jin-Sook Kwon, Meizi Li, Young-Hwa Kim, Hainan Piao, Bo-Ra Son, Tae-Jin Youn, 
Dong-Woon Kim, Myeong-Chan Cho, Chungbuk National University Hospital, Cheongju, 
South Korea 
Human immunodefiwncy virus type-l (lentivirus) based vectors have a number of 
attractive features for gene therapy including the ability to transduce non-dividing cells 
and long term transgene expresslo”. We have investigated the efficiency of foreign gene 
delivery using a lentiviral vector into HeLa cells, human umbilical vein endothelial cells 
(HUVECs), primary cultured rat aorta smooth muscle cells (VSMCs). pleuripotent mes- 
enchymal stem cells (MSCs) obtained from rat bone marrow and non-dividing well-differ- 
entiated cells lnclcding postmitotlc beating neonatal rat cardiomyocytes (CMs). Using 
IantiViral vectors containing a variety of strong promoters and pseudotyped with the 
vesicular stomatitis virus-G glycoproteln, we successfully generated versatile high-titer 
lentivirus at titers of up to 5X10* infection unit (lU)/ml, and improved transduction effi- 
ciency in various cell types. This lentiviral system was able to deliver enhanced green flu- 
~rescence protein (GFP) and P-galactosidase reporter genes with high transduction 
efhciency into HeLa cells (97% by FACS). HUVECs. MSCs and CMs (80%, 30%. 30% by 
IF. respectively). While both l-antiviral and retroviral vectors effectively transduce HeLa 
cells, HUVECs and MSCs, lentiviral vectors at titers of 2X1@ IU/ml also efficiently trans- 
duce CMs but retroviral vectors showed very low transduction efficiency. Lentiviral vec- 
tors also mediate efficient delwery of therapeutic genes (eNOS or hVEGF121 gene) into 
VSMCs or MSCs, and NO and VEGF were secreted Into the supernatant of cultured 
cells. When lentwal vectors expressing GFP were directly injected into the hind legs of 
rat, transduction of nondivldmg skeletal myocytes could be demonstrated until 10 weeks 
after gene d&very, which was not the case when retroviral vectors were used. Taken 
together, these results demonstrate that lentivirus-based vectors can efficiently trans- 
duce both undiffferentiated and well-differentiated cells in vitro and in viva. Therefore, 
lentivirus-mediated gene transfer strategies provide an efficient tool for in viva gene ther- 
apy and ax viva modification of MSCs to provide a new tool for research and therapy for 
cardiovascular diseases. 
4:30 p.m. 
865-3 Overexpression of Tumor Necrosis Factor-a in 
Cardiomyocytes Migrates Embryonic Stem Cells 
Yu Chen Yinke Yang, Jamal S. Rana, Qingen Ke, James P. Morgan, Yang-Fu Xiao. -I 
Harvard Medical School, Boston, MA 
Tumor necorsis factor-a (TNF-a) plays an important role in pathogenesis of myocardial 
infarction and heart failure. Also, TNF-a has been shown to active and enhance migration 
of vascular smooth muscle cells, neutrophils, and Langerhans cells. The present study 
investigated whether TNF-a was able to enhance migration of embryonic stem cells 
(ESCs) in vitro. Neonatal rat cardiomyocytes with or without transfectlon of TNF-a cDNA 
were cultured in the low comparlments of transwells. Mouse ESCs transfected with 
green fluorescent protein (GFP) cDNA were added to the upper compartments of tran- 
swells with 5-mm Dora filters. The content of TNF-a in the culture medium of the lower 
compartments of transwells was increased from 49;tZl pgiml to 1301 f 53 for the control 
cardiomyocytes (n=8) and for the TNF-a-transfected cardiomyocytes (n=8. PcO.001). 
respectively. lmmunostainlng for TNF-a showed that the control cardiomywytes almost 
did not express the cytokine. In contrast, positive staining for TNF-a was very intense in 
the TNF-a-transfected cardiomyocyies. Overexpression of TNF-a in cultured cardiomyo- 
cyies transfected with TNF-a-cDNA significantly enhanced migration of ESCs to the low 
compartments. In the control group. 1272 f 449 GFP-positive ESCs were detected in 
each 10000 cells collected from the low compartments and sorted by flow cytometry. 
However, m the TNF-a-transfected cardiomyocytes, the number of migrated GFP-posi- 
tive ESCs was increased by 44%, to 1829 d 579 cells/l0000 cells (n=8, P<O.OOl). More- 
over, the enhancement of TNF-a induced migration of ESCs was blocked by pra- 
incubation of ESCs for 60min with antibody (3mg/ml) against the Type II TNF-a receptor 
(TNFR-~75. 1305 * 465 GFP-positive cells/l0000cells, n=4). These results demonstrate 
that TNF-a enhanced ESC migration from one culture compartment to another. This 
enhancement of ESC migration might result from an activation of type II TNF-a receptor 
on the membrane of ESCs. Our study may provide important Information for the under- 
standing of the cause of stem cell homing to injured myocardium. 
4:45 pm. 
865-4 Aspirin Protects Cardiac Myocytes From Apoptosis by 
Modulating Mitogen-Activated Protein Kinases 
En Iwai-Kanal, Tetsuhiko Yanazume, Tomoyuki Oda, Soulchi Adachi, Naoya Sowa. 
Masatoshi Fujita, Koji Hasegawa, Kyoto University Kyoto, Japan, College of Medical 
Technology. Kyoto University, Kyoto. Japan 
Background: Aspirin, as an anti-thrombotic agent, is now widely used for primary or sec- 
ondary prophylaxis against myocardial infarction. Aspirin not only inhibits prostaglandm 
biosynthesis but also directly acts on intracellular signaling molecules. These include AP- 
I, NF-kB. mitogen-activated protein kinases (MAPKs). and heat shock proteins. These 
signaling molecules are related to regulation of apoptosis. Since myocardial cell loss due 
to apoptosis has been suggested to contribute to remodeling after myocardial infarction, 
we investigated effects of aspirin on myocardial cell apoptosis. 
Methods: Primary cardiac myocytes prepared from neonatal rats were treated with p- 
adrenergic agonist isoproterenol (1O-5 M), hydrogen peroxide (H20z, 1 O-5 M), or saline 
as a control in the serum free medium for 48 hours. Then, we investigated regulation of 
MAPKs during aspirin-mediated protection of cardiac myocytes from ho,-induced apo- 
ptos1s. 
Results: Stimulation with isoproterenol or H,O, induced apoptosls m cardiac myocyies. 
evidenced by increase in TUNEL-positive myocytes, their typical morphologic features, 
and decreased mitochondrial membrane potential shown by cytofluorimetric analysis. 
Administration of a therapeutic concentration of aspirin (5 mM) almost completely inhib- 
ited myocardial cell apoptws induced by w.?proterenol or l+O,. Administration of YO, 
alone resulted in slight activation of ERK (extracellular responsive kinase) 112 and in 
moderate activation of p38 MAPK. Administrating aspirin in addition to t$O, further 
potentiated t$O,-induced ERKIR activation. Administration of PD098059. a MEK-I- 
specific inhibitor, negated the anti-apoptotic effect of aspirin on cardiac myocytes, indi- 
cating the cardio-protection of aspirin requires activation of ERKi/P. In contrast, aspirin 
inhibited t$O,-induced activation of p38MAPK to the control level. 
Conclusion:These findings provide the first evidence that aspirin is a potent anti-apop- 
